8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Mar 5, 2026·SEC
Core Laboratories N.V.(CLB)Earnings, Financials & Key Ratios
CLB•NYSE
18.7× P/E·Price updated Jun 15, 2026
AboutCore Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. In addition, the company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. It operates approximately in 50 countries. The company was founded in 1936 and is based in Amstelveen, the Netherlands.Show more
- Revenue$527M+0.5%
- EBITDA$64M-13.6%
- Net Income$32M+1.3%
- EPS (Diluted)0.68+3.0%
- Gross Margin17.91%+6.1%
- EBITDA Margin12.06%-14.1%
- Operating Margin9.28%-17.0%
- Net Margin6.04%+0.8%
- ROE11.83%-8.1%
- ROIC8.31%-19.7%
- Debt/Equity0.74+5.5%
- Interest Coverage4.95+4.6%
CLB Key Insights
Core Laboratories N.V. (CLB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 2.5% through buybacks
✗Weaknesses
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CLB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLB Price & Volume
Core Laboratories N.V. (CLB) stock price & volume — 10-year historical chart
Loading chart...
CLB Growth Metrics
Core Laboratories N.V. (CLB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-4.07%
5 Years1.56%
3 Years2.44%
TTM1.34%
Profit CAGR
10 Years-12.05%
5 Years-
3 Years17.8%
TTM11.21%
EPS CAGR
10 Years-12.82%
5 Years-
3 Years17.42%
TTM8.93%
Return on Capital
10 Years11.8%
5 Years10.19%
3 Years11%
Last Year9.94%
CLB Recent Earnings
Core Laboratories N.V. (CLB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
Apr 29, 2026EPS
$0.06
Est $0.06
+0.0%
Revenue
$122M
Est $123M
-1.0%
Q1 2026
Feb 4, 2026EPS
$0.21
Est $0.19
+9.8%
Revenue
$138M
Est $132M
+4.6%
Q4 2025
Oct 22, 2025EPS
$0.22
Est $0.19
+15.8%
Revenue
$135M
Est $129M
+4.6%
Q3 2025
Jul 23, 2025EPS
$0.19
Est $0.18
+5.6%
Revenue
$130M
Est $131M
-0.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.06vs $0.06+0.0% | $122Mvs $123M-1.0% |
| Q1 2026 | Feb 4, 2026 | $0.21vs $0.19+9.8% | $138Mvs $132M+4.6% |
| Q4 2025 | Oct 22, 2025 | $0.22vs $0.19+15.8% | $135Mvs $129M+4.6% |
| Q3 2025 | Jul 23, 2025 | $0.19vs $0.18+5.6% | $130Mvs $131M-0.6% |
Based on last 12 quarters of dataView full earnings history →
CLB Peer Comparison
Core Laboratories N.V. (CLB) competitors in Seismic and Reservoir Evaluation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LBRT | 4.55B | 28.07 | 31.54 | -7.16% | 3.71% | 7.39% | 0.42 | |
 NINE | 441.77M | 10.20 | -8.16 | 1.41% | 11.52% | |||
 PUMP | 1.86B | 15.19 | 1947.44 | -12.13% | -1.05% | -1.43% | 0.30 | |
 PTEN | 4.04B | 10.65 | -44.38 | -10.25% | -2.56% | -3.67% | 0.40 | |
 RES | 1.53B | 6.89 | 45.93 | 14.95% | 1.2% | 1.91% | 0.09 | |
 WTTR | 2.08B | 18.49 | 92.43 | -3.08% | 1.54% | 2.21% | 0.40 | |
 SLB | 80.63B | 53.71 | 22.86 | -1.6% | 9.38% | 13.88% | 0.45 | |
 HAL | 31.89B | 38.18 | 25.45 | -3.31% | 6.95% | 14.59% | 0.77 |
Compare CLB vs Peers
Core Laboratories N.V. (CLB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLB Income Statement
Core Laboratories N.V. (CLB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 659.81M | 700.85M | 668.21M | 487.27M | 470.25M | 489.74M | 509.79M | 523.85M | 526.52M | 524.73M |
Revenue Growth % | 10.94% | 6.22% | -4.66% | -27.08% | -3.49% | 4.14% | 4.1% | 2.76% | 0.51% | 1.34% |
Cost of Goods Sold | 499.18M | 520.05M | 495.58M | 385.14M | 386.41M | 410.82M | 415.74M | 435.48M | 432.24M | 431.12M |
COGS % of Revenue | 75.66% | 74.2% | 74.17% | 79.04% | 82.17% | 83.89% | 81.55% | 83.13% | 82.09% | - |
Gross Profit | 160.63M▲ 0% | 180.79M▲ 12.6% | 172.63M▼ 4.5% | 102.13M▼ 40.8% | 83.84M▼ 17.9% | 78.92M▼ 5.9% | 94.05M▲ 19.2% | 88.37M▼ 6.0% | 94.28M▲ 6.7% | 93.61M▲ 0% |
Gross Margin % | 24.34% | 25.8% | 25.83% | 20.96% | 17.83% | 16.11% | 18.45% | 16.87% | 17.91% | 17.84% |
Gross Profit Growth % | 28.27% | 12.55% | -4.52% | -40.84% | -17.9% | -5.87% | 19.17% | -6.04% | 6.69% | - |
Operating Expenses | 47.74M | 62.91M | 75.95M | 178.93M | 38.58M | 37.4M | 39.41M | 29.82M | 45.43M | 41.06M |
OpEx % of Revenue | 7.23% | 8.98% | 11.37% | 36.72% | 8.2% | 7.64% | 7.73% | 5.69% | 8.63% | - |
Selling, General & Admin | 47.74M | 62.91M | 46.52M | 32.53M | 44.17M | 38.12M | 38.89M | 38.59M | 45.43M | 46.5M |
SG&A % of Revenue | 7.23% | 8.98% | 6.96% | 6.68% | 9.39% | 7.78% | 7.63% | 7.37% | 8.63% | - |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | -452K | 0 | 29.43M | 146.4M | -5.59M | -722K | 515K | -8.78M | 0 | -1000K |
Operating Income | 112.44M▲ 0% | 118.62M▲ 5.5% | 96.68M▼ 18.5% | -76.81M▼ 179.4% | 45.26M▲ 158.9% | 41.52M▼ 8.3% | 54.64M▲ 31.6% | 58.56M▲ 7.2% | 48.85M▼ 16.6% | 52.55M▲ 0% |
Operating Margin % | 17.04% | 16.93% | 14.47% | -15.76% | 9.63% | 8.48% | 10.72% | 11.18% | 9.28% | 10.01% |
Operating Income Growth % | 30.47% | 5.5% | -18.49% | -179.44% | 158.93% | -8.26% | 31.59% | 7.17% | -16.57% | - |
EBITDA | 136.96M | 141.71M | 119.29M | -55.94M | 63.78M | 58.69M | 70.42M | 73.51M | 63.5M | 70.96M |
EBITDA Margin % | 20.76% | 20.22% | 17.85% | -11.48% | 13.56% | 11.98% | 13.81% | 14.03% | 12.06% | 13.52% |
EBITDA Growth % | 21.15% | 3.46% | -15.82% | -146.89% | 214.02% | -7.99% | 20% | 4.38% | -13.61% | 2.5% |
D&A (Non-Cash Add-back) | 24.52M | 23.09M | 22.61M | 20.87M | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M | 18.41M |
EBIT | 109.97M | 118.62M | 102.02M | 49.63M | 45.26M | 41.52M | 54.64M | 58.56M | 48.85M | 52.55M |
Net Interest Income | -10.73M | -13.33M | -14.69M | -14.37M | -9.15M | -11.57M | -13.43M | -12.37M | -9.86M | -10.15M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 10.73M | 13.33M | 14.69M | 14.37M | 9.15M | 11.57M | 13.43M | 12.37M | 9.86M | 10.15M |
Other Income/Expense | -8.26M | -13.33M | -14.69M | -14.37M | -9.15M | -11.57M | -13.43M | -12.37M | -2.96M | -9.47M |
Pretax Income | 101.71M▲ 0% | 105.29M▲ 3.5% | 81.99M▼ 22.1% | -91.18M▼ 211.2% | 36.11M▲ 139.6% | 29.95M▼ 17.0% | 41.21M▲ 37.6% | 46.19M▲ 12.1% | 45.9M▼ 0.6% | 43.08M▲ 0% |
Pretax Margin % | 15.41% | 15.02% | 12.27% | -18.71% | 7.68% | 6.12% | 8.08% | 8.82% | 8.72% | 8.21% |
Income Tax | 18.61M | 25.45M | -12.29M | 5.9M | 15.89M | 10.3M | 4.18M | 14.03M | 13.37M | 11.37M |
Effective Tax Rate % | 18.3% | 24.17% | -14.99% | -6.47% | 44.01% | 34.37% | 10.16% | 30.39% | 29.13% | 26.4% |
Net Income | 83.13M▲ 0% | 79.53M▼ 4.3% | 101.98M▲ 28.2% | -97.64M▼ 195.7% | 19.73M▲ 120.2% | 19.45M▼ 1.4% | 36.67M▲ 88.5% | 31.4M▼ 14.4% | 31.8M▲ 1.3% | 31.17M▲ 0% |
Net Margin % | 12.6% | 11.35% | 15.26% | -20.04% | 4.2% | 3.97% | 7.19% | 5.99% | 6.04% | 5.94% |
Net Income Growth % | 30.1% | -4.33% | 28.24% | -195.74% | 120.2% | -1.39% | 88.53% | -14.38% | 1.28% | 11.21% |
Net Income (Continuing) | 80.98M | 79.85M | 94.28M | -97.07M | 20.16M | 19.66M | 37.02M | 32.15M | 32.52M | 31.7M |
Discontinued Operations | 2.11M | 0 | 7.83M | -424K | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 3.89M | 4.14M | 4.28M | 4.06M | 4.55M | 4.7M | 4.99M | 5.75M | 0 | 0 |
EPS (Diluted) | 1.88▲ 0% | 1.79▼ 4.8% | 2.10▲ 17.3% | -2.16▼ 202.9% | 0.42▲ 119.4% | 0.42▲ 0.0% | 0.77▲ 83.3% | 0.66▼ 14.3% | 0.68▲ 3.0% | 0.68▲ 0% |
EPS Growth % | 29.66% | -4.79% | 17.32% | -202.86% | 119.44% | 0% | 83.33% | -14.29% | 3.03% | 8.93% |
EPS (Basic) | 1.88 | 1.80 | 2.11 | -2.18 | 0.43 | 0.42 | 0.79 | 0.67 | 0.68 | - |
Diluted Shares Outstanding | 44.26M | 44.47M | 44.65M | 44.97M | 46.69M | 46.81M | 47.52M | 47.69M | 46.5M | 46.07M |
Basic Shares Outstanding | 44.15M | 44.21M | 44.36M | 44.48M | 46.01M | 46.33M | 46.68M | 46.9M | 46.5M | 46.07M |
Dividend Payout Ratio | 116.86% | 122.29% | 95.68% | - | 9.3% | 9.53% | 5.09% | 5.97% | 5.88% | - |
CLB Balance Sheet
Core Laboratories N.V. (CLB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 207.43M | 230.98M | 221.24M | 165.85M | 189.06M | 211.7M | 223.14M | 226.61M | 222.37M | 214.37M |
Cash & Short-Term Investments | 14.4M | 13.12M | 11.09M | 13.81M | 17.7M | 15.43M | 15.12M | 19.16M | 22.85M | 22.82M |
Cash Only | 14.4M | 13.12M | 11.09M | 13.81M | 17.7M | 15.43M | 15.12M | 19.16M | 22.85M | 22.82M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 133.1M | 129.16M | 138.11M | 83.19M | 106.74M | 115.1M | 123.07M | 127.36M | 113.53M | 108.28M |
Days Sales Outstanding | 73.63 | 67.26 | 75.44 | 62.32 | 82.85 | 85.79 | 88.11 | 88.74 | 78.7 | 82.55 |
Inventory | 33.32M | 45.66M | 50.16M | 38.15M | 45.44M | 60.45M | 71.7M | 59.4M | 54.5M | 57.78M |
Days Inventory Outstanding | 24.36 | 32.05 | 36.95 | 36.16 | 42.92 | 53.7 | 62.95 | 49.79 | 46.02 | 48.74 |
Other Current Assets | 14.02M | 27.69M | 5.92M | 15.9M | 5.11M | 5.06M | 5.09M | 10.52M | 31.5M | 25.49M |
Total Non-Current Assets | 377.38M | 417.85M | 553.44M | 402.73M | 391.8M | 366.65M | 363.26M | 363.8M | 374.59M | 373.36M |
Property, Plant & Equipment | 123.1M | 122.92M | 199.2M | 181.68M | 172.34M | 157.41M | 153.47M | 153.55M | 153.79M | 166.79M |
Fixed Asset Turnover | 5.36x | 5.70x | 3.35x | 2.68x | 2.73x | 3.11x | 3.32x | 3.41x | 3.42x | 3.29x |
Goodwill | 179.04M | 219.41M | 213.43M | 99.44M | 99.44M | 99.44M | 99.44M | 99.44M | 0 | 218.66M |
Intangible Assets | 9.4M | 13.05M | 17.45M | 8.58M | 8.14M | 7.48M | 6.93M | 6.4M | 220.79M | 0 |
Long-Term Investments | 3.56M | 3.76M | 3.97M | 4.09M | 4.16M | 4.45M | 4.84M | 5.08M | 0 | 0 |
Other Non-Current Assets | -14.28M | -15.01M | 52.08M | 36.16M | 37.26M | 29.3M | 98.58M | 29.71M | 0 | -12.1M |
Total Assets | 584.81M▲ 0% | 648.83M▲ 10.9% | 774.67M▲ 19.4% | 568.58M▼ 26.6% | 580.85M▲ 2.2% | 578.35M▼ 0.4% | 586.39M▲ 1.4% | 590.41M▲ 0.7% | 596.95M▲ 1.1% | 587.73M▲ 0% |
Asset Turnover | 1.13x | 1.08x | 0.86x | 0.86x | 0.81x | 0.85x | 0.87x | 0.89x | 0.88x | 0.88x |
Asset Growth % | 2.05% | 10.95% | 19.4% | -26.6% | 2.16% | -0.43% | 1.39% | 0.68% | 1.11% | -0.33% |
Total Current Liabilities | 105.02M | 102.55M | 111.59M | 89.75M | 90.78M | 103.14M | 88.1M | 97.59M | 107.17M | 104.73M |
Accounts Payable | 41.7M | 41.16M | 35.61M | 23.03M | 29.73M | 45.85M | 33.51M | 34.55M | 37.27M | 39.98M |
Days Payables Outstanding | 30.49 | 28.88 | 26.23 | 21.82 | 28.08 | 40.73 | 29.42 | 28.96 | 31.48 | 33 |
Short-Term Debt | 0 | 0 | 11.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 17.07M | 17.32M | 13.38M | 5.46M | 7.76M | 5.94M | 4.75M | 9.33M | 0 | 16.37M |
Other Current Liabilities | 29.99M | 18.6M | 17.75M | 14.96M | 13.61M | 13.18M | 13.59M | 8.16M | 58.44M | 64.75M |
Current Ratio | 1.98x | 2.25x | 1.98x | 1.85x | 2.08x | 2.05x | 2.53x | 2.32x | 2.07x | 2.05x |
Quick Ratio | 1.66x | 1.81x | 1.53x | 1.42x | 1.58x | 1.47x | 1.72x | 1.71x | 1.57x | 1.50x |
Cash Conversion Cycle | 67.5 | 70.43 | 86.16 | 76.65 | 97.7 | 98.76 | 121.65 | 109.57 | 93.24 | 98.3 |
Total Non-Current Liabilities | 331.06M | 385.38M | 480.94M | 403.26M | 329.07M | 286.26M | 268.49M | 235.08M | 210.02M | 207.85M |
Long-Term Debt | 226.99M | 289.77M | 305.28M | 259.43M | 188.64M | 172.39M | 163.13M | 126.11M | 152.56M | 41.28M |
Capital Lease Obligations | 0 | 0 | 64.66M | 56.11M | 49.29M | 38.3M | 42.08M | 43.34M | 42.31M | 126.25M |
Deferred Tax Liabilities | 5.32M | 7.63M | 27.34M | 20.59M | 24.34M | 22.88M | 12.7M | 13.78M | 0 | 21.58M |
Other Non-Current Liabilities | 45.96M | 37.22M | 33.17M | 27.98M | 27.71M | 20.88M | 20.04M | 51.85M | 15.15M | 166.56M |
Total Liabilities | 436.08M | 487.93M | 592.53M | 493.01M | 419.85M | 389.4M | 356.59M | 332.67M | 317.19M | 312.58M |
Total Debt | 226.99M | 289.77M | 381.78M | 326.98M | 250.26M | 222.39M | 215.38M | 180.14M | 206.33M | 41.28M |
Net Debt | 212.59M | 276.65M | 370.69M | 313.17M | 232.56M | 206.96M | 200.26M | 160.99M | 183.48M | 18.47M |
Debt / Equity | 1.49x | 1.76x | 2.10x | 4.33x | 1.55x | 1.18x | 0.94x | 0.70x | 0.74x | 0.15x |
Debt / EBITDA | 1.66x | 2.04x | 3.20x | - | 3.92x | 3.79x | 3.06x | 2.45x | 3.25x | 0.58x |
Net Debt / EBITDA | 1.55x | 1.95x | 3.11x | - | 3.65x | 3.53x | 2.84x | 2.19x | 2.89x | 0.26x |
Interest Coverage | 10.24x | 8.90x | 6.94x | 3.45x | 4.95x | 3.59x | 4.07x | 4.73x | 4.95x | 5.18x |
Total Equity | 152.62M▲ 0% | 165.04M▲ 8.1% | 182.14M▲ 10.4% | 75.57M▼ 58.5% | 161M▲ 113.0% | 188.95M▲ 17.4% | 229.81M▲ 21.6% | 257.74M▲ 12.2% | 279.76M▲ 8.5% | 275.14M▲ 0% |
Equity Growth % | -4.16% | 8.14% | 10.36% | -58.51% | 113.04% | 17.36% | 21.62% | 12.15% | 8.55% | 31.6% |
Book Value per Share | 3.45 | 3.71 | 4.08 | 1.68 | 3.45 | 4.04 | 4.84 | 5.40 | 6.02 | 5.97 |
Total Shareholders' Equity | 148.73M | 160.9M | 177.87M | 71.51M | 156.45M | 184.26M | 224.81M | 251.99M | 279.76M | 275.14M |
Common Stock | 1.15M | 1.15M | 1.15M | 1.15M | 1.19M | 1.19M | 469K | 470K | 279.76M | 0 |
Retained Earnings | 173.85M | 156.13M | 160.54M | 50.46M | 68.35M | 85.95M | 120.76M | 150.28M | 0 | 0 |
Treasury Stock | -76.27M | -52.5M | -29.36M | -14.07M | -4.08M | -1.36M | -1.45M | -2.54M | 0 | 0 |
Accumulated OCI | -8.35M | -5.46M | -6.33M | -7.2M | -10.13M | -3.78M | -4.97M | -5.77M | 0 | 0 |
Minority Interest | 3.89M | 4.14M | 4.28M | 4.06M | 4.55M | 4.7M | 4.99M | 5.75M | 0 | 0 |
CLB Cash Flow Statement
Core Laboratories N.V. (CLB) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 124.27M | 111.83M | 89.53M | 57.87M | 36.58M | 24.96M | 24.79M | 56.39M | 37.18M | 35.1M |
Operating CF Margin % | 18.83% | 15.96% | 13.4% | 11.88% | 7.78% | 5.1% | 4.86% | 10.76% | 7.06% | - |
Operating CF Growth % | -5.77% | -10.01% | -19.94% | -35.36% | -36.79% | -31.78% | -0.67% | 127.47% | -34.07% | -151.31% |
Net Income | 83.1M | 79.79M | 93.71M | -96.92M | 20.22M | 19.66M | 37.02M | 32.15M | 31.8M | 31.17M |
Depreciation & Amortization | 24.94M | 23.09M | 22.61M | 20.87M | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M | 14.7M |
Stock-Based Compensation | 22.94M | 34.19M | 20.88M | 7.39M | 19.09M | 7.76M | 13.97M | 3.75M | 7.14M | 7.47M |
Deferred Taxes | 9.02M | 1.83M | -36.34M | -12.22M | 6.01M | 433K | -10.81M | 674K | -4.74M | -6.6M |
Other Non-Cash Items | -6.32M | -17.18M | -478K | 132.81M | -3.01M | 4.97M | -2.41M | -3.03M | -6.11M | -8.29M |
Working Capital Changes | -9.4M | -9.89M | -10.84M | 5.94M | -24.25M | -25.02M | -28.77M | 7.88M | -5.57M | -3.67M |
Change in Receivables | -18.57M | 2.27M | -3.19M | 46.42M | -13.52M | -10.08M | -2.62M | -3.61M | -4.95M | 5.72M |
Change in Inventory | 446K | -10.4M | -3.89M | 1.47M | -4.55M | -14.86M | -12.98M | 9.37M | 2.64M | -475.66K |
Change in Payables | 8.72M | -1.75M | -3.76M | -12.84M | 6.57M | 15.37M | -12.88M | 519K | 477K | 565.34K |
Cash from Investing | -20.56M | -70.64M | -5.68M | 7.85M | -10.22M | -3.86M | -6.65M | -6.39M | -2.23M | -6.57M |
Capital Expenditures | -18.77M | -21.74M | -22.27M | -11.88M | -13.54M | -10.22M | -10.58M | -13.03M | 0 | -11.32M |
CapEx % of Revenue | 2.85% | 3.1% | 3.33% | 2.44% | 2.88% | 2.09% | 2.08% | 2.49% | 2.77% | 2.16% |
Acquisitions | 0 | -47.31M | 2.98M | 1.51M | 873K | 240K | 0 | 0 | -1.24M | -210.07K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -18.45M | -23.24M | -6.77M | 18.22M | -11.82M | 6.12M | 3.93M | 6.63M | -994K | 4.96M |
Cash from Financing | -104.08M | -42.47M | -85.87M | -63.01M | -22.46M | -23.38M | -18.45M | -45.96M | -31.25M | -27.4M |
Debt Issued (Net) | 10M | 64M | 15M | -46M | -71M | -15M | -9M | -38M | -16.71M | -13.02M |
Equity Issued (Net) | -16.91M | -7.45M | -3.31M | -2.79M | 51.74M | -3.9M | -2.2M | -5.31M | -12.43M | -10.53M |
Dividends Paid | -97.14M | -97.25M | -97.57M | -12.45M | -1.83M | -1.85M | -1.87M | -1.88M | -1.87M | -1.89M |
Share Repurchases | -16.91M | -7.45M | -3.31M | -2.79M | -8.26M | -3.9M | -2.2M | -5.31M | -12.43M | -14.52M |
Other Financing | -26K | -1.77M | 8K | -1.77M | -1.37M | -2.62M | -5.38M | -775K | -254K | -1.96M |
Net Change in Cash | -364K▲ 0% | -1.28M▼ 252.7% | -2.02M▼ 57.6% | 2.71M▲ 234.1% | 3.9M▲ 43.6% | -2.27M▼ 158.4% | -308K▲ 86.5% | 4.04M▲ 1410.7% | 3.69M▼ 8.6% | 857K▲ 0% |
Free Cash Flow | 105.5M▲ 0% | 90.09M▼ 14.6% | 67.26M▼ 25.3% | 45.99M▼ 31.6% | 23.04M▼ 49.9% | 14.74M▼ 36.0% | 14.21M▼ 3.6% | 43.36M▲ 205.1% | 22.59M▼ 47.9% | 23.83M▲ 0% |
FCF Margin % | 15.99% | 12.85% | 10.07% | 9.44% | 4.9% | 3.01% | 2.79% | 8.28% | 4.29% | 4.54% |
FCF Growth % | -12.22% | -14.61% | -25.34% | -31.62% | -49.9% | -36.02% | -3.6% | 205.14% | -47.91% | -45.8% |
FCF per Share | 2.38 | 2.03 | 1.51 | 1.02 | 0.49 | 0.31 | 0.30 | 0.91 | 0.49 | 0.52 |
FCF Conversion (FCF/Net Income) | 1.49x | 1.41x | 0.88x | -0.59x | 1.85x | 1.28x | 0.68x | 1.80x | 1.17x | 0.76x |
Interest Paid | 10.53M | 11.5M | 13.63M | 11.67M | 10.48M | 9.3M | 11.2M | 10.86M | 0 | 2.49M |
Taxes Paid | 24.31M | 31.93M | 13.8M | 21.32M | 18.13M | 28.16M | 29.07M | 28.44M | 0 | 4.66M |
CLB Key Ratios
Core Laboratories N.V. (CLB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 53.31% | 50.07% | 58.75% | -75.77% | 16.68% | 11.12% | 17.52% | 12.88% | 11.83% | 11.34% |
| Return on Invested Capital (ROIC) | 23.23% | 22.05% | 14.58% | -12.24% | 8.68% | 7.89% | 9.92% | 10.35% | 8.31% | 9.91% |
| Gross Margin | 24.34% | 25.8% | 25.83% | 20.96% | 17.83% | 16.11% | 18.45% | 16.87% | 17.91% | 17.84% |
| Net Margin | 12.6% | 11.35% | 15.26% | -20.04% | 4.2% | 3.97% | 7.19% | 5.99% | 6.04% | 5.94% |
| Debt / Equity | 1.49x | 1.76x | 2.10x | 4.33x | 1.55x | 1.18x | 0.94x | 0.70x | 0.74x | 0.15x |
| Interest Coverage | 10.24x | 8.90x | 6.94x | 3.45x | 4.95x | 3.59x | 4.07x | 4.73x | 4.95x | 5.18x |
| FCF Conversion | 1.49x | 1.41x | 0.88x | -0.59x | 1.85x | 1.28x | 0.68x | 1.80x | 1.17x | 0.76x |
| Revenue Growth | 10.94% | 6.22% | -4.66% | -27.08% | -3.49% | 4.14% | 4.1% | 2.76% | 0.51% | 1.34% |
Related:CLB Dividend History·CLB Revenue History·CLB Price History·CLB P/E History·CLB Financial Ratios·CLB Institutional Holders
CLB SEC Filings & Documents
Core Laboratories N.V. (CLB) SEC filings — annual & quarterly reports (10-K, 10-Q)
CLB Frequently Asked Questions
Core Laboratories N.V. (CLB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Core Laboratories N.V. (CLB) reported $524.7M in revenue for fiscal year 2025. This represents a 398% increase from $105.4M in 1996.
Core Laboratories N.V. (CLB) grew revenue by 0.5% over the past year. Growth has been modest.
Yes, Core Laboratories N.V. (CLB) is profitable, generating $31.2M in net income for fiscal year 2025 (6.0% net margin).
Dividend & Returns
Yes, Core Laboratories N.V. (CLB) pays a dividend with a yield of 0.32%. This makes it attractive for income-focused investors.
Core Laboratories N.V. (CLB) has a return on equity (ROE) of 11.8%. This is reasonable for most industries.
Core Laboratories N.V. (CLB) generated $23.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.